RxDoctor Payments Data

Sarah Norris

Family · Loris, SCNPI 1841285483

Payments from drug & device makers

$5,985in general payments, 2019–2025

Across 296 payments — averaging $20.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$718
  • AstraZeneca$611
  • Phathom Pharmaceuticals, Inc.$490
  • Abbott$401
  • Lilly USA, LLC$340
  • AbbVie$300
  • plus $3K from 38 others

What the payments were for

  • Food & beverage$5,985100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,985 in reported general payments places this provider in the 90th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$76,195
Medicare patients
174
Services billed
1,422

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide82$102,168
JardianceEmpagliflozin34$47,855
FarxigaDapagliflozin Propanediol45$41,645
EliquisApixaban64$39,998
JanuviaSitagliptin Phosphate22$32,511
TrulicityDulaglutide26$26,797
MounjaroTirzepatide13$17,170
XareltoRivaroxaban13$11,922
Stiolto RespimatTiotropium Br/Olodaterol Hcl14$8,349
Breo ElliptaFluticasone/Vilanterol12$7,107
BrilintaTicagrelor12$4,777
Gabapentin191$4,418
Potassium Chloride89$4,361
Albuterol Sulfate HfaAlbuterol Sulfate158$4,337
Lantus SolostarInsulin Glargine,hum.Rec.Anlog34$3,578

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$718$102,16882 claims
Boehringer IngelheimJardiance, Stiolto Respimat$204$56,20548 claims
AstraZenecaFarxiga, Brilinta$611$46,42357 claims
Lilly USA, LLCTrulicity, Mounjaro$340$43,96739 claims
PfizerEliquis$151$39,99864 claims
MerckJanuvia$14$32,51122 claims
Johnson & JohnsonXarelto$85$11,92213 claims
GSKBreo Ellipta$262$7,10712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,248 family providers in South Carolina.

Other family in Loris

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →